The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C

Journal of Interferon and Cytokine Research

Volumn 34, Issue 9, 2014, Pages 727-733

  Shehab, Hany ^a   Elbaz, Tamer ^a   Deraz, Dalia ^b   Hafez, Amal ^b   Elattar, Inas ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b Internal Medicine Department National Railway Hospital Center   (Egypt)

^c NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; VIRUS RNA;

ADULT; COMBINATION DRUG THERAPY; DRUG EFFECTS; EGYPT; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; MALE; METABOLISM; MIDDLE AGED; PICHIA; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PICHIA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906854992     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0127     Document Type: Article

References (34)

1. Abdo AA, Al-Ahdal MN, Khalid SS, and others. 2013. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int 7:533-538.
2. Antaki N, Bibert S, Kebbewar K, and others. 2013. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J Viral Hepat 20:59-64.
3. Asselah T, De Muynck S, Broët P, and others. 2012. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 56:527-532.
4. Dawson B, Trapp GT. 2001. Basic and Clinical Biostatistics, 3rd edition, Lange medical book, Appleton & Lange, Norwalk, Connecticut.
5. De Nicola S, Aghemo A, Rumi MG, and others. 2012. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C. Hepatology 55:336-342.
6. Derbala M, Rizk NM, Al-Kaabi S, and others. 2013. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Virology 444:292-300.
7. Division of Microbiology and Infectious Diseases (DMID), table for grading the severity of adult and pediatric adverse events. 2007. Available at www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/ dmidadulttox.pdf
8. Egyptian Ministry of Health. 2007. Annual report. Available at www.mohp.gov.eg/Main.asp
9. El Raziky M, Fathalah WF, El-Akel WA, and others. 2013. The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: a single centre Egyptian study. Hepat Mon 13:e10069.
10. Esmat G, Abdel-Fattah S. 2009. Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis C-genotype 4. Dig Liver Dis Suppl 3:17-19.
11. Esmat G, Abouzied AM, Adel-Aziz F, Strickland T. 2003. Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin. Hepatology 38:324A.
12. Ferenci P, Laferl H, Scherzer TM, and others. 2008. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135:451-458.
13. Fried MW, Shiffman ML, Reddy R, and others. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
14. Gellissen G. 2002. Hansenula polymorpha-biology and applications. Weinheim: Wiley-VCH, p 352.
15. Jacobson IM, McHutchison JG, Dusheiko G, and others. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405-2416.
16. Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Á lvarez M, Resino S. 2013. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 11:6.
17. Kamal SM, El Kamary SS, Shardell MD, and others. 2007. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 46:1732-1740.
18. Kamal SM, El Tawil AA, Nakano T, and others. 2005. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 54:858-866.
19. Kamal SM, Nasser IA. 2008. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 47:1371-1383.
20. Khairy M, Abdel-Rahman M, El-Raziky M, and others. 2012. Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon 12:e6718.
21. Khuroo MS, Khuroo MS, Dahab ST. 2004. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 20:931-938.
22. Kim YJ, Jang BK, Kim ES, and others. 2012. Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients. Korean J Hepatol 18:41-47.
23. Lawitz E, Lalezari JP, Hassanein T, and others. 2013a. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 13:401-408.
24. Lawitz E, Mangia A, Wyles D, and others. 2013b. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 16:1878-1887.
25. Manns MP, McHutchison JG, Gordon SC, and others. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
26. McHutchison J, Lawitz E, Shiffman M, and others. 2009. Peginterferon Alfa-2b or Alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361:580-593.
27. Pol S, Ghalib RH, Rustgi VK, and others. 2012. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebocontrolled, dose-finding, phase 2a trial. Lancet Infect Dis 12:671-677.
28. Poordad F, McCone J, Jr., Bacon BR, and others. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195-1206.
29. Rossignol JF, Elfert A, El-Gohary Y, Keefe EB. 2009. Improved virologic response in chronic hepatitis C genotype 4 patients given nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136:856-862.
30. Shehab HM, Elbaz TM, Deraz DM. 2014. Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial. Liver Int 34:259-265.
31. Taha A, El-Ray A, El-Ghannam M, Mounir B. 2010. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 10:597-602.
32. Urquijo JJ, Diago M, Boadas J, and others. 2013. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Ann Hepatol 12:30-35.
33. Youssef SS, Abd El-Aal A, Saad A, and others. 2013. Impact of IL12B gene rs 3212227 polymorphism on fibrosis, liver inflammation, and response to treatment in genotype 4 Egyptian hepatitis C patients. Dis Markers 35:431-437.
34. Zayed N, Awad AB, El-Akel W, and others. 2013. The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 37:254-261.